Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 503 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Non-fasting Clear all

Conditions: Temporomandibular Disorders
Interventions: Chiropractic w/Activator & Self Care, Dental Care & Self Care, Sham AMCT, Self-Care Only Group; Device · Other
Lead sponsor: Palmer College of Chiropractic; Other
Eligibility: 21 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: Coralville, Iowa • Davenport, Iowa • Iowa City, Iowa

Conditions: Cystic Fibrosis
Interventions: Magnetic resonance relaxometry, Magnetic resonance spectroscopy, Blood Draw, DXA, pQCT; Diagnostic Test
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 13 Years to 20 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Validation Study
Interventions: Neural Sleeve and Zeno walkway; Device
Lead sponsor: Cionic, Inc.; Industry
Eligibility: 22 Years to 64 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Healthy
Interventions: Ondansetron, Zofran®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type II, Diabetes Mellitus, Adult-Onset, Inflammation
Interventions: Victoza (liraglutide) with dietician monitoring, Placebo with dietician monitoring; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 40 Years to 69 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Stanford, California

Conditions: Pancreatic Cancer
Interventions: HCP-Guided Exercise Training Program; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Brain Metastases From HER2 and Breast Cancer, Advanced HER2-positive Breast Cancer
Interventions: ARRY-380 Twice Daily Dosage, ARRY-380 Once Daily, Trastuzumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Healthy Volunteers
Interventions: SPD422, Omeprazole; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Metabolic Syndrome, Pre-diabetes
Interventions: Time-restricted eating (TRE) + Standard of Care, Standard of Care; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 75 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Nerve Injury, Prostate Cancer
Interventions: 4-Aminopyridine, Placebo; Drug · Other
Lead sponsor: John Elfar; Other
Eligibility: 45 Years to 75 Years · Male only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 2
States / cities: Tucson, Arizona • Rochester, New York

Conditions: Dose Finding Study
Interventions: TAK-828, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 2
States / cities: Baltimore, Maryland • Austin, Texas

Conditions: Healthy
Interventions: Dexmethylphenidate Hydrochloride; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Lung Cancer Stage III
Interventions: AN0025; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Healthy
Interventions: Imlunestrant (Test), Imlunestrant (Reference), Omeprazole; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 343 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: South Miami, Florida • Lenexa, Kansas • Springfield, Missouri + 2 more

Conditions: Healthy Volunteers
Interventions: Questionnaire, Stool sample, Skin swab, Oral rinse; Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Infections, Bacterial
Interventions: GSK1322322 1000 mg containing radioactive 14C-GSK1322322, GSK1322322 1200 mg containing radioactive 14C-GSK1322322; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 30 Years to 55 Years · Male only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Endometrial Cancer, Obesity
Interventions: Dietary Intervention, Informational Material, Dietary Education, Weight Maintenance, Average score of Obesity and Weight-Loss Quality of Life Questionnaire; Dietary Supplement · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Childhood Cancer Survivors
Interventions: Children's Oncology Group Heart Health Link, Monthly weights, Fasting, Calls, Participant Questionnaires, Dried blood spot; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 4
States / cities: New York, New York • Memphis, Tennessee • Seattle, Washington

Conditions: HER2-positive Breast Cancer
Interventions: Doxorubicin, cyclophosphamide, paclitaxel, docetaxel, Trastuzumab, Pertuzumab; Drug
Lead sponsor: Western Regional Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Goodyear, Arizona

Conditions: Cancer, Diet, Healthy, Nutrition, Healthy
Interventions: Food pantry referrals, No-prep, ready-to-eat meals, Vouchers; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy Volunteer
Interventions: ABBV-101; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Fibrous Dysplasia/McCune-Albright Syndrome
Interventions: MRI-based Neuroimaging, Non-contrast MRI, 18F-FDG-PET/CT, 18F-NaF-PET/CT; Diagnostic Test
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 10 Years to 45 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pregnancy Preterm, Neonatal Hypoglycemia, Hyperglycemia Drug Induced
Interventions: Maternal glycemic control; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Birmingham, Alabama • Chapel Hill, North Carolina

Conditions: Diabetes Mellitus, Type 2, PreDiabetes, Pancreas Cyst, Chronic Pancreatitis, Genetic Predisposition to Disease, Inherited Disease
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 1,250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Omaha, Nebraska

Search by objective public record fields.

Conservative Treatment of Patients With Temporomandibular Disorders

Skeletal Health and Bone Marrow Composition in Adolescents With Cystic Fibrosis

Gait Metric Validation of the Cionic Neural Sleeve

Ondansetron HCl Orally Disintegrating Tablets Under Non-Fasting Conditions

Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood

Feasibility of a Health Care Provider Guided Exercise Intervention Prior to Surgical Resection of Pancreatic Cancer

ARRY-380 + Trastuzuamab for Breast w/ Brain Mets

Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of SPD422 (Anagrelide Hydrochloride) in Healthy Adult Participants

Long Term Impact of Time-Restricted Eating on Parameters of Cardiometabolic Health

4-aminopyridine Treatment for Nerve Injury

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants

Dexmethylphenidate Hydrochloride Tablets Under Non-Fasting Conditions

A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants

A Study of Imlunestrant (LY3484356) in Healthy Female Participants

Human Skin and Gut Mycobiome and Bacteriome Comprehensive Registry

A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 After an Intravenous and an Oral Dose

Protein-Sparing Modified Fast Intervention for Weight Loss in Obese Endometrial Cancer Survivors

A Study of Time-Restricted Eating in Childhood Cancer Survivors

Fasting on Newly Diagnosed Breast Cancer

Screening for and Responding to Food Insecurity Among Infusion Patients

A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants

Pain in Fibrous Dysplasia

Euglycemia After Antenatal Late Preterm Steroids, the E-ALPS Study

Blood Markers of Early Pancreas Cancer